Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing?
<p dir="ltr">Cardiovascular disease (CVD) continues to be a leading cause of global mortality and morbidity. Various established risk factors are linked to CVD, and modifying these risk factors is fundamental in CVD management. Clinical studies underscore the association between dysl...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513555500367872 |
|---|---|
| author | Mohammad Al Zein (20090700) |
| author2 | Alicia Khazzeka (20090703) Alessandro El Khoury (20090706) Jana Al Zein (20090709) Dima Zoghaib (20090712) Ali H. Eid (5461829) |
| author2_role | author author author author author |
| author_facet | Mohammad Al Zein (20090700) Alicia Khazzeka (20090703) Alessandro El Khoury (20090706) Jana Al Zein (20090709) Dima Zoghaib (20090712) Ali H. Eid (5461829) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohammad Al Zein (20090700) Alicia Khazzeka (20090703) Alessandro El Khoury (20090706) Jana Al Zein (20090709) Dima Zoghaib (20090712) Ali H. Eid (5461829) |
| dc.date.none.fl_str_mv | 2024-10-21T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.pcad.2024.10.009 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Revisiting_high-density_lipoprotein_cholesterol_in_cardiovascular_disease_Is_too_much_of_a_good_thing_always_a_good_thing_/27574386 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology HDL-raising therapies Coronary artery disease Cardiovascular disease Atherosclerosis Apolipoprotein A-1, dyslipidemia |
| dc.title.none.fl_str_mv | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing? |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Cardiovascular disease (CVD) continues to be a leading cause of global mortality and morbidity. Various established risk factors are linked to CVD, and modifying these risk factors is fundamental in CVD management. Clinical studies underscore the association between dyslipidemia and CVD, and therapeutic interventions that target low-density lipoprotein cholesterol elicit clear benefits. Despite the correlation between low high-density lipoprotein cholesterol (HDLC) and heightened CVD risk, HDL-raising therapies have yet to showcase significant clinical benefits. Furthermore, evidence from epidemiological and genetic studies reveals that not only low HDL-C levels, but also very high levels of HDL-C are linked to increased risk of CVD. In this review, we focus on HDL metabolism and delve into the relationship between HDL and CVD, exploring HDL functions and the observed alterations in its roles in disease. Altogether, the results discussed herein support the conventional wisdom that “too much of a good thing is not always a good thing”. Thus, our recommendation is that a careful reconsideration of the impact of high HDL-C levels is warranted, and shall be revisited in future research.</p><h2>Other Information</h2><p dir="ltr">Published in: Progress in Cardiovascular Diseases<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.pcad.2024.10.009" target="_blank">https://dx.doi.org/10.1016/j.pcad.2024.10.009</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_45f5b2e6085620440b7f7816b3c0a5ff |
| identifier_str_mv | 10.1016/j.pcad.2024.10.009 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/27574386 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing?Mohammad Al Zein (20090700)Alicia Khazzeka (20090703)Alessandro El Khoury (20090706)Jana Al Zein (20090709)Dima Zoghaib (20090712)Ali H. Eid (5461829)Biomedical and clinical sciencesCardiovascular medicine and haematologyHDL-raising therapiesCoronary artery diseaseCardiovascular diseaseAtherosclerosisApolipoprotein A-1, dyslipidemia<p dir="ltr">Cardiovascular disease (CVD) continues to be a leading cause of global mortality and morbidity. Various established risk factors are linked to CVD, and modifying these risk factors is fundamental in CVD management. Clinical studies underscore the association between dyslipidemia and CVD, and therapeutic interventions that target low-density lipoprotein cholesterol elicit clear benefits. Despite the correlation between low high-density lipoprotein cholesterol (HDLC) and heightened CVD risk, HDL-raising therapies have yet to showcase significant clinical benefits. Furthermore, evidence from epidemiological and genetic studies reveals that not only low HDL-C levels, but also very high levels of HDL-C are linked to increased risk of CVD. In this review, we focus on HDL metabolism and delve into the relationship between HDL and CVD, exploring HDL functions and the observed alterations in its roles in disease. Altogether, the results discussed herein support the conventional wisdom that “too much of a good thing is not always a good thing”. Thus, our recommendation is that a careful reconsideration of the impact of high HDL-C levels is warranted, and shall be revisited in future research.</p><h2>Other Information</h2><p dir="ltr">Published in: Progress in Cardiovascular Diseases<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.pcad.2024.10.009" target="_blank">https://dx.doi.org/10.1016/j.pcad.2024.10.009</a></p>2024-10-21T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.pcad.2024.10.009https://figshare.com/articles/journal_contribution/Revisiting_high-density_lipoprotein_cholesterol_in_cardiovascular_disease_Is_too_much_of_a_good_thing_always_a_good_thing_/27574386CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/275743862024-10-21T03:00:00Z |
| spellingShingle | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing? Mohammad Al Zein (20090700) Biomedical and clinical sciences Cardiovascular medicine and haematology HDL-raising therapies Coronary artery disease Cardiovascular disease Atherosclerosis Apolipoprotein A-1, dyslipidemia |
| status_str | publishedVersion |
| title | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing? |
| title_full | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing? |
| title_fullStr | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing? |
| title_full_unstemmed | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing? |
| title_short | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing? |
| title_sort | Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing? |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology HDL-raising therapies Coronary artery disease Cardiovascular disease Atherosclerosis Apolipoprotein A-1, dyslipidemia |